Trial of Lay-led Individualised Self-management Education for Adults With Asthma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00129987 |
|
Recruitment Status :
Completed
First Posted : August 12, 2005
Results First Posted : January 29, 2020
Last Update Posted : January 29, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Asthma | Behavioral: Self management education | Not Applicable |
This study will be a randomised controlled trial looking for equivalence; the investigators' central hypothesis is that lay-led education will be at least equivalent to professional-led education in terms of patient outcomes. Patients will be randomised to receive either lay-led or professional led self-management education. Patients will be followed up longitudinally for 12 months from initial intervention. Two sites were studied; Manchester and London. It is anticipated that 16 sites will be recruited in each of the two geographical areas; all sites will have an asthma register. Individuals will be eligible for inclusion if they are adults; have clinician diagnosed asthma; have persistent disease and require regular therapy, with some evidence of variability in their disease, such that a self management plan would be appropriate. Both genders will be eligible, as will those unable to see or read. Individuals will be excluded if they have severe cognitive impairment; they decline to be randomised; they decline to receive asthma education and follow-up solely from the designated educator, other than in an emergency situation, or their condition does not show variability.
The intervention in the study will be a disease-specific asthma self-management education programme delivery either by a professional (ie practice nurse) or a lay educator. Both lay and professional trainers will receive specific training in the content and delivery of this intervention. The intervention will consist of an initial 45 minute training session (including receipt of a written personal asthma action plan); a second face to face reinforcing session 3 weeks after the first session; 3 monthly telephone follow-up appointments to reinforce messages and to give ongoing advice with availability of the nurse or lay educator as a source of advice at all other times. Data will be collected on unscheduled use of health care, peak flow readings, patients' self-reporting of "adverse events", RCP three questions, perceptions of the interviews using MISS-21, QOL questionnaire and AQLQ. Demographics for all patients will also be recorded.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 567 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | A Multi-centre Randomised Trial of Lay-led Individualised Self-management Education for Adults With Asthma |
| Actual Study Start Date : | November 2003 |
| Actual Primary Completion Date : | July 2006 |
| Actual Study Completion Date : | August 2006 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Nurse group
An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
|
Behavioral: Self management education |
|
Experimental: Lay educator group
An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
|
Behavioral: Self management education |
- Number of Participants With Unscheduled Use of Healthcare [ Time Frame: 1 year ]Healthcare consists of one or other of hospital admission, emergency department attendance, unscheduled consultation with a GP
- Lung Function [ Time Frame: 1 year ](peak flow measurement)
- Quality of Life Questionnaires [ Time Frame: 1 year ](MISS-21) with Quality of life questionnaires
- Number of Participants With Use of Asthma Medication [ Time Frame: 1 year ]Number of participants with courses of steriod tablets
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adults step two therapy (BTS)
- Evidence of poorly controlled disease
Exclusion Criteria:
- Unable to benefit from self management education
- Other respiratory conditions other than asthma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129987
| United Kingdom | |
| NHLI at Charing Cross Hospital Campus | |
| London, United Kingdom, W6 8RF | |
| Principal Investigator: | Martyn R Partridge, MD FRCP | NHLI Imperial College |
Other Publications:
| Responsible Party: | Imperial College London |
| ClinicalTrials.gov Identifier: | NCT00129987 |
| Other Study ID Numbers: |
NHLICX3224 |
| First Posted: | August 12, 2005 Key Record Dates |
| Results First Posted: | January 29, 2020 |
| Last Update Posted: | January 29, 2020 |
| Last Verified: | January 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Asthma |
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |

